These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 16641354

  • 1. Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience.
    Heesakkers RA, Fütterer JJ, Hövels AM, van den Bosch HC, Scheenen TW, Hoogeveen YL, Barentsz JO.
    Radiology; 2006 May; 239(2):481-7. PubMed ID: 16641354
    [Abstract] [Full Text] [Related]

  • 2. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging.
    Heesakkers RA, Jager GJ, Hövels AM, de Hoop B, van den Bosch HC, Raat F, Witjes JA, Mulders PF, van der Kaa CH, Barentsz JO.
    Radiology; 2009 May; 251(2):408-14. PubMed ID: 19401573
    [Abstract] [Full Text] [Related]

  • 3. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?
    Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R.
    AJR Am J Roentgenol; 2006 Jan; 186(1):144-8. PubMed ID: 16357394
    [Abstract] [Full Text] [Related]

  • 4. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging.
    Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, Hulsbergen van de Kaa CA, Kaufmann D, Barentsz JO.
    Radiology; 2004 Nov; 233(2):449-56. PubMed ID: 15375228
    [Abstract] [Full Text] [Related]

  • 5. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging.
    Memarsadeghi M, Riedl CC, Kaneider A, Galid A, Rudas M, Matzek W, Helbich TH.
    Radiology; 2006 Nov; 241(2):367-77. PubMed ID: 17057065
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study.
    Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, Saini S, Maravilla KR, Feldman DE, Schmiedl UP, Brunberg JA, Francis IR, Harms SE, Som PM, Tempany CM, Group.
    Radiology; 2003 Sep; 228(3):777-88. PubMed ID: 12954896
    [Abstract] [Full Text] [Related]

  • 7. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging.
    Dinniwell R, Chan P, Czarnota G, Haider MA, Jhaveri K, Jewett M, Fyles A, Jaffray D, Milosevic M.
    Int J Radiat Oncol Biol Phys; 2009 Jul 01; 74(3):844-51. PubMed ID: 19095369
    [Abstract] [Full Text] [Related]

  • 8. Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10.
    Tatsumi Y, Tanigawa N, Nishimura H, Nomura E, Mabuchi H, Matsuki M, Narabayashi I.
    Gastric Cancer; 2006 Jul 01; 9(2):120-8. PubMed ID: 16767368
    [Abstract] [Full Text] [Related]

  • 9. Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging.
    Thoeny HC, Froehlich JM, Triantafyllou M, Huesler J, Bains LJ, Vermathen P, Fleischmann A, Studer UE.
    Radiology; 2014 Oct 01; 273(1):125-35. PubMed ID: 24893049
    [Abstract] [Full Text] [Related]

  • 10. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging.
    Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, Motoori K, Ueda T.
    Radiology; 2006 Apr 01; 239(1):122-30. PubMed ID: 16493012
    [Abstract] [Full Text] [Related]

  • 11. Improved detection of hepatic metastases from pancreatic cancer using periodically rotated overlapping parallel lines with enhanced reconstruction (PROPELLER) technique after SPIO administration.
    Hirokawa Y, Isoda H, Okada T, Arizono S, Shimada K, Yamamoto A, Shibata T, Togashi K.
    Invest Radiol; 2010 Mar 01; 45(3):158-64. PubMed ID: 20142748
    [Abstract] [Full Text] [Related]

  • 12. USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience.
    Philips BWJ, Stijns RCH, Rietsch SHG, Brunheim S, Barentsz JO, Fortuin AS, Quick HH, Orzada S, Maas MC, Scheenen TWJ.
    Eur Radiol; 2019 Dec 01; 29(12):6529-6538. PubMed ID: 31201525
    [Abstract] [Full Text] [Related]

  • 13. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research.
    Simon GH, Raatschen HJ, Wendland MF, von Vopelius-Feldt J, Fu Y, Chen MH, Daldrup-Link HE.
    Acad Radiol; 2005 Sep 01; 12(9):1190-7. PubMed ID: 16099684
    [Abstract] [Full Text] [Related]

  • 14. Lymph node metastasis: ultrasmall superparamagnetic iron oxide-enhanced MR imaging versus PET/CT in a rabbit model.
    Choi SH, Moon WK, Hong JH, Son KR, Cho N, Kwon BJ, Lee JJ, Chung JK, Min HS, Park SH.
    Radiology; 2007 Jan 01; 242(1):137-43. PubMed ID: 17090719
    [Abstract] [Full Text] [Related]

  • 15. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria.
    Lahaye MJ, Engelen SM, Kessels AG, de Bruïne AP, von Meyenfeldt MF, van Engelshoven JM, van de Velde CJ, Beets GL, Beets-Tan RG.
    Radiology; 2008 Mar 01; 246(3):804-11. PubMed ID: 18195379
    [Abstract] [Full Text] [Related]

  • 16. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation.
    Harisinghani MG, Saini S, Weissleder R, Hahn PF, Yantiss RK, Tempany C, Wood BJ, Mueller PR.
    AJR Am J Roentgenol; 1999 May 01; 172(5):1347-51. PubMed ID: 10227514
    [Abstract] [Full Text] [Related]

  • 17. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience.
    Bellin MF, Roy C, Kinkel K, Thoumas D, Zaim S, Vanel D, Tuchmann C, Richard F, Jacqmin D, Delcourt A, Challier E, Lebret T, Cluzel P.
    Radiology; 1998 Jun 01; 207(3):799-808. PubMed ID: 9609907
    [Abstract] [Full Text] [Related]

  • 18. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide.
    Nishimura H, Tanigawa N, Hiramatsu M, Tatsumi Y, Matsuki M, Narabayashi I.
    J Am Coll Surg; 2006 Apr 01; 202(4):604-11. PubMed ID: 16571430
    [Abstract] [Full Text] [Related]

  • 19. The Potential of Iron Oxide Nanoparticle-Enhanced MRI at 7 T Compared With 3 T for Detecting Small Suspicious Lymph Nodes in Patients With Prostate Cancer.
    Tenbergen CJA, Fortuin AS, van Asten JJA, Veltien A, Philips BWJ, Hambrock T, Orzada S, Quick HH, Barentsz JO, Maas MC, Scheenen TWJ.
    Invest Radiol; 2024 Jul 01; 59(7):519-525. PubMed ID: 38157433
    [Abstract] [Full Text] [Related]

  • 20. MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10.
    Harisinghani MG, Dixon WT, Saksena MA, Brachtel E, Blezek DJ, Dhawale PJ, Torabi M, Hahn PF.
    Radiographics; 2004 Jul 01; 24(3):867-78. PubMed ID: 15143236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.